Seminars in Cancer Biology

Article	Citations
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation	473
Multifaceted role of chemokines in solid tumors: From biology to therapy	456
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation	349
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications	292
Targeting Hippo signaling pathway by phytochemicals in cancer therapy	260
Editorial Board	243
Advances in biology and novel treatments of SCLC	237
Small secretory proteins of immune cells can modulate gynecological cancers	234
The molecular chaperone TRAP1 in cancer: From the basics of biology to pharmacological targeting	233
Emerging applications of bacteria as antitumor agents	224
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator	202
Deregulated transcription factors in the emerging cancer hallmarks	195
Critical DNA damaging pathways in tumorigenesis	192
Origins and molecular effects of hypoxia in cancer	187
Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]	187
Editorial Board	185
Editorial Board	185
Special issue: Deregulated transcription factors in the cancer therapeutic challenges: An update on cancer stemness features	184
The impact of obesity and lipids on cancer: Insights into mechanisms and potential interventions	184
Innovative trial design in precision oncology	179
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy	164
Gut microbes in gastrointestinal cancers	163
The IL-1 family in tumorigenesis and antitumor immunity	159
Molecular targets of tyrosine kinase inhibitors in thyroid cancer	152
Genome chaos: Creating new genomic information essential for cancer macroevolution	149

Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis	145
Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives	145
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer	144
Immune cellular components and signaling pathways in the tumor microenvironment	142
Cracking the Resistance Code:The Molecular Reclassification of Cancer and Precision Therapy Strategies	139
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers	134
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?	125
Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse	123
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives	120
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy	119
Anticancer properties of chimeric HDAC and kinase inhibitors	119
Atrial fibrillation in cancer patients: Epidemiology, identification and management	117
Reprogramming of glycolysis by chemical carcinogens during tumor development	116
Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging	116
Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways	116
Anticancer natural products targeting immune checkpoint protein network	116
Editorial Board	114
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools	113
Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems	112
Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer	112
The role of deiodinases on metabolic alteration in cancer	111
Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy	109
New biological and immunological approaches to cancer therapy: Basic and clinical aspects	109
Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers	107
Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy	107
Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma	107
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine	104
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics	104
Cellular stress responses and metabolic reprogramming in cancer progression and dormancy	102
Vibrational spectroscopy for decoding cancer microbiota interactions: Current evidence and future perspective	99
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors	99
The intricacies of NRF2 regulation in cancer	99
Curcumin and colorectal cancer: An update and current perspective on this natural medicine	99
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics	98
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer	98
How far have we explored fungi to fight cancer?	97
Editorial Board	96
Editorial Board	95
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment	94
The foundational framework of tumors: Gametogenesis, p53, and cancer	93
Analytical demands to use whole-genome sequencing in precision oncology	92
Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer	91
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer	91
Metabolic reprogramming of tumor microenviroment by engineered bacteria	91
Clinical utility of whole-genome sequencing in precision oncology	90
Cytotoxic activity of l-lysine alpha-oxidase against leukemia cells	89
Drivers of centrosome abnormalities: Senescence progression and tumor immune escape	88
Mechanisms and applications of apolipoproteins and apolipoprotein mimetic peptides: Common pathways in cardiovascular disease and cancer	87
Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy	87
Advancements in small cell lung cancer	85

The microbiome-immune cell interaction network: Advancing tumor immunotherapy	85
The role of RNA processing and regulation in metastatic dormancy	85
Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy	84
Chaperonins in cancer: Expression, function, and migration in extracellular vesicles	83
The role of tumor microenvironment and exosomes in dormancy and relapse	82
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer	82
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders	82
Microbiota and lung cancer	82
Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy	81
Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications	79
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling	78
Epithelial-mesenchymal transition: Insights into nickel-induced lung diseases	77
Microorganisms in cancer tertiary lymphoid structure formation	77
Paradoxes of cancer: Survival at the brink	75
Sanitation enzymes: Exquisite surveillance of the noncanonical nucleotide pool to safeguard the genetic blueprint	74
Holistic immunomodulation for small cell lung cancer	74
CRISPR/Cas mediated epigenome editing for cancer therapy	73
Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity	72
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications	71
Pattern recognition of tumor dormancy and relapse beyond cell-intrinsic and cell-extrinsic pathways	71
Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme	71
Arsenic co-carcinogenesis: Inhibition of DNA repair and interaction with zinc finger proteins	71
Chemopreventive effects of anthocyanins on colorectal and breast cancer: A review	71
Urinary microbiota and bladder cancer: A systematic review and a focus on uropathogens	71
Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment	70
Targeting tumor cell senescence and polyploidy as potential therapeutic strategies	70
Anticancer activity of lactic acid bacteria	70
Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer	70
Microbes in gynecologic cancers: Causes or consequences and therapeutic potential	70
Excess body weight: Novel insights into its roles in obesity comorbidities	69
Targeting p53 for the treatment of cancer	69
Editorial Board	68
Thematic issue ‘tumor glycolysis’	68
Molecular mechanisms of pulmonary carcinogenesis by polycyclic aromatic hydrocarbons (PAHs): Implications for human lung cancer	68
Editorial Board	68
Deregulated transcription factors and poor clinical outcomes in cancer patients	67
The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives	67
SR-BI as a target of natural products and its significance in cancer	66
The impact of VEGF on cancer metastasis and systemic disease	65
Special Issue: Epigenetic regulation of cancer progression: Promises and progress	65
Editorial Board	64
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges	64
Characterizing and exploiting the many roles of aberrant H2B monoubiquitination in cancer pathogenesis	64
Non-coding genome in small cell lung cancer between theoretical view and clinical applications	64
The intricate role of adipokines in cancer-related signaling and the tumor microenvironment: Insights for future research	63
Human cell polyploidization: The good and the evil	63
Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer	63
Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives	61
Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects	61
TGF-β, EMT, and resistance to anti-cancer treatment	61
Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers	60
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance	60
Alternative splicing in EMT and TGF-β signaling during cancer progression	59
Gut microbiota and immunosenescence in cancer	59
cGAS/STING signalling pathway in senescence and oncogenesis	59
Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges	58
Transcriptional factors targeting in cancer stem cells for tumor modulation	58
The intricate nature of senescence in development and cell plasticity	58
Putting the brakes on tumorigenesis with snake venom toxins: New molecular insights for cancer drug discovery	58
Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: A comprehensive analysis and future directions	57
Remodeling of tumor microenvironment by cellular senescence and immunosenescence in cervical cancer	57
Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective	57
Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developments	57
Editorial Board	57
Emerging role of pancreatic stellate cell-derived extracellular vesicles in pancreatic cancer	56
The role of RNA-binding proteins in the processing of mRNAs produced by carcinogenic papillomaviruses	56
Precision diagnostics in lymphomas – Recent developments and future directions	56
Role of endolysosome function in iron metabolism and brain carcinogenesis	56
Extracellular vesicles as source for the identification of minimally invasive molecular signatures in glioblastoma	56
Contributions of the distinct biophysical phenotype of polyploidal giant cancer cells to cancer progression	56
The Warburg effect: The hacked mitochondrial-nuclear communication in cancer	55
Microbiome unlocks cancer immunotherapeutic potential: State of the art and future	55
Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?	55
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities	54
Artificial intelligence aids in development of nanomedicines for cancer management	54
Editorial Board	53
Corrigendum to “How far have we explored fungi to fight cancer?” [86/Part 2 (2022) 976–989]	53
Editorial Board	53
Targeting oncogenic transcription factors in skin malignancies: An update on cancer stemness and therapeutic outcomes	52
The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community	52

Inflammation targeted nanomedicines: Patents and applications in cancer therapy	52
Editorial Board	52
Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)	51
Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis	51
Nanoparticles: Attractive tools to treat colorectal cancer	51
Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs	51
The role of exercise in obesity-related cancers: Current evidence and biological mechanisms	51
Pro-tumoral functions of tumor-associated macrophage EV-miRNA	50
Predictive biomarkers for response to immune checkpoint inhibition	50
“Time” for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment	50
Vitamin D: What role in obesity-related cancer?	50
The altered lipidome of hepatocellular carcinoma	50
Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways	50
Precision medicine in pediatric solid cancers	49
Interplay of ferroptosis, cuproptosis, and PANoptosis in cancer treatment-induced cardiotoxicity: Mechanisms and therapeutic implications	49
New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy	49
Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity	49
A role for partial epithelial-to-mesenchymal transition in enabling stemness in homeostasis and cancer	48
Regulation of cancer cell signaling pathways as key events for therapeutic relevance of edible and medicinal mushrooms	48
Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy	47
Small cell lung cancer: Novel treatments beyond immunotherapy	46
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy	46
Dysregulated FOXM1 signaling in the regulation of cancer stem cells	46
Hedgehog signaling mechanism and role in cancer	46
Impaired cholesterol and LDL uptake pathways in the development of oncological and cardiovascular diseases	46
Dynamical hallmarks of cancer: Phenotypic switching in melanoma and epithelial-mesenchymal plasticity	45
Understanding RNA-binding proteins	45
Radiotherapy-induced remodeling of the tumor microenvironment by stromal cells	45
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease	45
Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities	45
Ethical challenges of precision cancer medicine	45
Recent advances of nanodrug delivery system in the treatment of hematologic malignancies	45
Sphingolipids in embryonic development, cell cycle regulation, and stemness – Implications for polyploidy in tumors	44
Lipids and lipoproteins in the interstitial tissue fluid regulate the formation of dysfunctional tissue-resident macrophages: Implications for atherogenic, tumorigenic, and obesogenic processes	44
The two sides of Hippo pathway in cancer	44
Microbial polysaccharides: An emerging family of natural biomaterials for cancer therapy and diagnostics	44
The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions	44
An update on vitamin D signaling and cancer	43
Lactate Dehydrogenase and its clinical significance in pancreatic and thoracic cancers	43
Polyploid giant cancer cell characterization: New frontiers in predicting response to chemotherapy in breast cancer	43
RB functions as a key regulator of senescence and tumor suppression	43
Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer	43
Editorial Board	43
Nutrient sensing of mTORC1 signaling in cancer and aging	43
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis	42
Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC	42
Epigenetic Regulation of Cancer Immune Cells	42
New approaches for targeting platinum-resistant ovarian cancer	42
Obesity and renal cell carcinoma: Biological mechanisms and perspectives	42
Harnessing computational spatial omics to explore the spatial biology intricacies	41
Towards artificial intelligence to multi-omics characterization of tumor heterogeneity in esophageal cancer	41
Targeting cancer stem cells by nutraceuticals for cancer therapy	41
Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy	41
Nanomedicines targeting the inflammasome as a promising therapeutic approach for cell senescence	41
A systems and computational biology perspective on advancing CAR therapy	40
Vaginal microbiome and cervical cancer	40
Insulin resistance in cancer risk and prognosis	40
Inflammasomes in cancer: Effect of epigenetic and autophagic modulations	40
Long-term recurrence of PDAC after resection for IPMN: A narrative review of the literature on clinical and biologic predictors	40
Special issue on “Excess body weight and cancer: Novel biologic insights and challenges”	40
Targeting stemness of cancer stem cells to fight colorectal cancers	40
Connecting the dots in the associations between diet, obesity, cancer, and microRNAs	40
Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy	39
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better	38
Thorny ground, rocky soil: Tissue-specific mechanisms of tumor dormancy and relapse	38
Chemokine clouding and liver cancer heterogeneity: Does it impact clinical outcomes?	38
The cell cycle revisited: DNA replication past S phase preserves genome integrity	38
Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications	37
Status quo of Extracellular Vesicle isolation and detection methods for clinical utility	37
Cancer cell populations	37
Epigenetic regulation of CXCR4 signaling in cancer pathogenesis and progression	37
Corrigendum to “Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers” [Semin. Cancer Biol. 83 (2022) 556–569]	37
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments	37
The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells	37
Immunosenescence in skeletal muscle: The role-play in cancer cachexia chessboard	37
Chemokine-mucinome interplay in shaping the heterogeneous tumor microenvironment of pancreatic cancer	37
Special issue: Modulation of immune checkpoint proteins and their networks in cancer progression	37
Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin	37
Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems	37
Multiple endocrine neoplasia type 2: A review	37
Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany	37
Polyploidy in development and tumor models in Drosophila	37
Editorial Board	36
Editorial Board	36
Counter regulation of tumor angiogenesis by vascular endothelial growth factor and thrombospondin-1	36
Editorial: Regulating cell cycle-related activities: The right target for cancer therapy	36
High-Throughput immunogenetics for precision medicine in cancer	36
The potential of liquid biopsy in the management of cancer patients	36
Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma	36
Extracellular vesicles for precision medicine in prostate cancer – Is it ready for clinical translation?	36
Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review	36
Natural compounds modulate the crosstalk between apoptosis- and autophagy-regulated signaling pathways: Controlling the uncontrolled expansion of tumor cells	36
Clonal hematopoiesis, cardiovascular disease and cancer treatment-induced cardiotoxicity	36
Targeting intratumoral hypoxia to enhance anti-tumor immunity	35
Obesity associated pancreatic ductal adenocarcinoma: Therapeutic challenges	35